Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Döhner
K
K
Schlenk
R F
RF
van der Reijden
B A
BA
Döhner
H
H
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D003561:Cytarabine / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000235:genetics*; D005047:Etoposide / Q000008:administration & dosage; D017353:Gene Deletion; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D017404:In Situ Hybridization, Fluorescence; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics*; D008942:Mitoxantrone / Q000008:administration & dosage; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D000074081:MutS Homolog 3 Protein; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction
D003561:Cytarabine; D004268:DNA-Binding Proteins; D005047:Etoposide; D015255:Idarubicin; D008942:Mitoxantrone; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D000074081:MutS Homolog 3 Protein; C078444:MSH3 protein, human; C421109:multidrug resistance-associated protein 1